BioCardia, Inc. and StemCardia, Inc. announced a long-term partnership to advance StemCardia?s investigational pluripotent stem cell product candidate for the treatment of heart failure. Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia?s cell therapy candidate through studies expected to result in FDA approval of an investigational new drug application (IND) and the anticipated Phase I/II clinical development to follow.